Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Pharmalink Raises SEK96 Million to Undertake Pivotal Studies with Lead Programs in Cancer Therapy and Renal Disease

23:06 EDT 3 Oct 2013 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
STOCKHOLM, October 4, 2013 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, today announces it has raised SEK96 million (€11m / US$15m) in a Series C financing round. The round was co-led by two of the ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Pharmalink Raises SEK96 Million to Undertake Pivotal Studies with Lead Programs in Cancer Therapy and Renal Disease"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story